MedPath

Nalbuphine as an Adjuvant to Local Anaesthetic Mixture in Peribulbar Cataract Surgery

Not Applicable
Completed
Conditions
Nalbuphine as an Adjuvant to L. A in Peribulbar Block for Cataract Surgery
Interventions
Registration Number
NCT03436836
Lead Sponsor
Cairo University
Brief Summary

Nalbuphine has been used as an adjuvant to bupivacaine in intrathecal, epidural, caudal anesthesia and peripheral nerve blocks showing an increase in the efficacy and the duration of postoperative analgesia.The aim of this study is evaluation of the effect of nalbuphine when used as an adjuvant to a local anesthetic mixture in peribulbar block undergoing cataract surgery

Detailed Description

44 patients (22 in each group) scheduled for elective cataract surgery using peribulbar block. Patients of Group N received local anesthetics received 6 ml of 0.5% bupivacaine 1 ml hyaluronidase (75 IU), and 4mg of Nalbuphine in 1 ml of saline (total 8 ml) and patients of Group C received 6 ml of 0.5% bupivacaine, 1 ml hyaluronidase (75 IU) and1 ml saline (total 8 ml).

Addition of nalbuphine to bupivacaine in peribulbar block is associated with reduced the time of onset of globe akinesia, increased the duration of globe akinesia and analgesia with better postoperative pain relief

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
40
Inclusion Criteria
  • patients aged 40-60 years.
  • both sex.
  • ASA physical status Ι&II.
  • Patient with axial globe length below 26
Exclusion Criteria
  • Refusal of the patient to participate in the study.
  • Coagulation abnormalities(INR>1.4).
  • More than ASA II.
  • High myopia with axial length more than 26 mm.
  • Mentally retarded patients and failure of proper communication as in deafness .
  • Morbidly obese patients(BMI>35)
  • Patients with glaucoma (increased IOP>20mmgh)
  • Patients with history of hypersensitivity to study drugs

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Group Clidocaine, bupivacaine, hyaluronidase , salinePatients of group C was received a mixture of 3 ml of 2% lidocaine, 4 ml of 0.5% bupivacaine with hyaluronidase (75 IU) and 1 ml normal saline
Group Nlidocaine, bupivacaine , hyaluronidasegroup N was received a mixture of 3 ml of 2% lidocaine, 4 ml of 0.5% bupivacaine with hyaluronidase (75IU) and 4mg of nalbuphine in 1 ml normal saline. Nalbuphine (20mg amp.) was prepared in 0.9% sodium chloride in 5mL syringe. If the block was inadequate after 10 minutes, a 2-4 ml supplementation of local anesthetics was given by the same technique and the patient was excluded from the study
Group NNalbuphinegroup N was received a mixture of 3 ml of 2% lidocaine, 4 ml of 0.5% bupivacaine with hyaluronidase (75IU) and 4mg of nalbuphine in 1 ml normal saline. Nalbuphine (20mg amp.) was prepared in 0.9% sodium chloride in 5mL syringe. If the block was inadequate after 10 minutes, a 2-4 ml supplementation of local anesthetics was given by the same technique and the patient was excluded from the study
Primary Outcome Measures
NameTimeMethod
Sensory block12 hours Postoperative

Duration of the sensory block

Secondary Outcome Measures
NameTimeMethod
Sensory block onset12 hours Postoperative

Onset of the sensory block

Adverse effects of the used drugs24 hours postoperatively

Adverse effects of the used drugs as nausea and vomiting

Satisfaction assessed at the end of surgical procedure by using a three-point scale6 hours Postoperative

Patient satisfaction and surgeon satisfaction

Motor block12 hours Postoperative

Duration of the motor block

Mean Arterial blood pressure24 hours postoperatively

Hemodynamic parameter as mean blood pressure(mmHg)

Trial Locations

Locations (2)

Ahmed Abdalla Mohamed

🇪🇬

Cairo, Egypt

Ahmed Abdalla

🇪🇬

Cairo, Egypt

© Copyright 2025. All Rights Reserved by MedPath